The design and development of an encounter tool to support shared decision making about preventing cardiovascular events.
The design and development of an encounter tool to support shared decision making about preventing cardiovascular events.
复制标题
DOI：
10.1016/j.pmedr.2022.101994
复制
发表时间：
2022-12
影响因子：
2.8
通讯作者：
Ridgeway, Jennifer L.
中科院分区：
文献类型：
--
作者：
Hartasanchez, Sandra A.;Hargraves, Ian G.;Clark, Jennifer E.;Gravholt, Derek;Brito, Juan P.;Branda, Megan E.;Gomez, Yvonne L.;Nautiyal, Vivek;Khurana, Charanjit S.;Thomas, Randal J.;Montori, Victor M.;Ridgeway, Jennifer L.
心血管疾病 (CVD) 高风险患者往往接受的强化预防护理较少。临床实践指南建议采用共同决策 (SDM) 来提高心血管疾病一级预防的质量。有一些工具可以在临床治疗过程中使用来促进 SDM，但据我们所知，没有任何 SDM 治疗工具可以支持有关可用生活方式和药物选择的对话，从而实现与患者目标和 CVD 风险一致的预防性护理。利用现有的最佳证据和以人为本的设计（在用户最终使用的情况下进行迭代设计），我们的团队开发了 SDM 遇到工具，CV Prevention Choice。迭代开发过程中的每个后续版本都通过在真实的预防性遭遇中进行测试来评估内容、有用性和可用性。该工具的最终版本包括一个计算器，可以估计患者在未来 10 年内发生重大动脉粥样硬化 CVD 事件的风险。介绍了生活方式和药物选择，以及它们的优点、缺点、成本和其他负担。然后显示所选预防计划所实现的风险降低，以支持协作审议和决策。美国的一项多中心试验正在评估 CV Prevention Choice 在实现风险一致的 CV 预防方面的有效性，同时确定提高 SDM 遭遇工具的采用及其在实践中的常规使用的最佳策略。
Patients at high risk for cardiovascular disease (CVD) tend to receive less intensive preventive care. Clinical practice guidelines recommend shared decision making (SDM) to improve the quality of primary CVD prevention. There are tools for use during the clinical encounter that promote SDM, but, to our knowledge, there are no SDM encounter tools that support conversations about available lifestyle and pharmacological options that can lead to preventive care that is congruent with patient goals and CVD risk. Using the best available evidence and human-centered design (iterative design in the context of ultimate use with users), our team developed a SDM encounter tool, CV Prevention Choice. Each subsequent version during the iterative development process was evaluated in terms of content, usefulness, and usability by testing it in real preventive encounters. The final version of the tool includes a calculator that estimates the patient’s risk of a major atherosclerotic CVD event in the next 10 years. Lifestyle and medication options are presented, alongside their pros, cons, costs, and other burdens. The risk reduction achieved by the selected prevention program is then displayed to support collaborative deliberation and decision making. A U.S. multicenter trial is estimating the effectiveness of CV Prevention Choice in achieving risk-concordant CV prevention while identifying the best strategies for increasing the adoption of the SDM encounter tool and its routine use in practice.
登录
查看更多内容
影响因子：
2.8
作者：
Sheridan SL;Draeger LB;Pignone MP;Keyserling TC;Simpson RJ Jr;Rimer B;Bangdiwala SI;Cai J;Gizlice Z
通讯作者：
Gizlice Z
影响因子：
4.4
作者：
Kunneman, Marleen;Montori, Victor M.;Hess, Erik P.
通讯作者：
Hess, Erik P.
DOI：
10.1016/j.mayocpiqo.2020.04.013
发表时间：
2020-08-01
期刊：
Mayo Clinic proceedings. Innovations, quality & outcomes
影响因子：
--
作者：
Espinoza Suarez, Nataly R;LaVecchia, Christina M;Brito, Juan P
通讯作者：
Brito, Juan P
影响因子：
3
作者：
Curran GM;Bauer M;Mittman B;Pyne JM;Stetler C
通讯作者：
Stetler C
影响因子：
3.6
作者：
Politi, Mary C.;Yen, Renata W.;Durand, Marie-Anne
通讯作者：
Durand, Marie-Anne